September 29, 2016 / 8:21 PM / 10 months ago

BRIEF-Prothena outlines phase 2 development strategy for PRX003

1 Min Read

Sept 29 (Reuters) - Prothena Corporation Plc :

* Plans to advance a phase 2 clinical study of PRX003 for treatment of Psoriatic Arthritis

* Interim analysis of ongoing phase 1B multiple ascending dose proof-of-biology study in patients with Psoriasis expected by mid-2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below